A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine

Summary

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-HBV-002.

Timeline

Start

2021-09-17

Primary completion

2023-09-25

Completion

2023-09-25

Outcome

Met primary endpoint

release “CVI-HBV-002 임상 1 상 탑라인 수령… 시험대상자 전원 혈청방어효과 중대 이상반응 없어 안전성도 우수한 것으로 확인” chabio.com ↗

Drugs

Indications